New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status.

- Jardiance (empagliflozin) reduced risk for the composite endpoint of cardiovascular death and hospitalization for heart failure, as well as serious adverse kidney outcomes, in adults with or without chronic kidney disease at baseline. The trial included people with and without diabetes

- Sub-analysis findings from the EMPEROR-Reduced phase III trial were presented at the American Society of Nephrology Kidney Week 2020

For more information click here.